Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02141308

OCT in Rare Chorioretinal Diseases

This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels.

The purpose of measuring blood flow in the retina and choroid is to 1.) determine if rare diseases in these structures causes a change in blood flow compared to healthy eyes and 2.) find out if areas of changed blood flow line up with areas of damage that appear on conventional testing.

Recruiting

Interested in participating?

Request Info

Key information

Age range

7 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Casey Eye Institute, Oregon Health & Science University

Portland, Oregon, 97239-3098, United States

Location status: Recruiting

Location contact

Andreas Lauer, MD

SUB_INVESTIGATOR

Christina Flaxel, MD

SUB_INVESTIGATOR

David Huang, MD, PhD

SUB_INVESTIGATOR

Denny Romfh, OD

CONTACT

[email protected]

503-494-4351

Eric Suhler, MD

SUB_INVESTIGATOR

John Campbell, MD, MPH

SUB_INVESTIGATOR

Kevin Lathrop

CONTACT

[email protected]

503-494-8024

Michael Klein, MD

SUB_INVESTIGATOR

Steven Bailey, MD

SUB_INVESTIGATOR

About this study

Optical coherence tomography (OCT) is an imaging technology that can perform non-contact cross-sectional imaging of retinal and choroidal tissue structure in real time by measuring the intensity of reflected light. Tomographic images are generated by scanning the optical probe beam across the tissue structure of interest. OCT has become one of the most widely used imaging technologies by ophthalmologists. Its advantages include being a non-contact imaging modality, having micron-level resolution, producing a digital image that can be viewed electronically, and providing a reproducible quantitative measurement. New functional OCT including Doppler OCT and OCT angiography may allow an assessment of retinal blood flow and do away with the need for the more invasive fluorescein angiography (FA) test.

Thus, if the diagnostic data provided by functional OCT are at least equivalent or superior to those achieved by FA, patients and healthcare providers could realize a substantial benefit in utilizing this technology in the evaluation of retinal vascular disease. Even in the scenario in which an FA is not usually clinically indicated, OCT angiography may provide information over that of standard OCT and clinical examination and history, that might help clinicians better understand the etiology of the disease, and may even help inform treatment response.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Subject-Level Criteria:

Inclusion a. Diagnosis of retinal or choroidal disease

Exclusion

  • Inability to give informed consent.
  • Inability to complete study tests within a 30 day period
  • Significant renal disease, defined as a history of chornic renal failure requiring dialysis or kidney transplant.
  • A condition that, in the opinion of the investigator, would preclude participation in the study (e.g. unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
  • Blood pressure > 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible.
  • Women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months due to unknown safety of fluorescein angiography.

Study-Eye Criteria:

Inclusion

a. Diagnosis of retinal or choroidal disease

Exclusion

  • Inability to maintain stable fixation for OCT imaging.
  • An ocular condition is present that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study (i.e. cataract)
  • Substantial cataract that, in the opinion of the investigator, is likely to decrease visual acuity by 3 lines or more (i.e. cataract would be reducing acuity to 20/40 or worse if the eye was otherwise normal).
  • Media opacity or otherwise that would prevent either fixation or ability to obtain adequate images as determined by the examiner.

Treatment and study plan

Primary outcomes

  1. Total Retinal and Choroidal Blood Flow

    Time frame: One year

    Determination whether disease affecting the retina and/or choroid shows a change in blood flow that differs from healthy eyes. Total retinal/choroidal blood flow will be measured in uL/min.

Study contacts

Contact information is provided by the study sponsor or research team.

Denny Romfh, OD

CONTACT

[email protected]

503-494-4351

Kevin Lathrop

CONTACT

[email protected]

503-494-8024

Sponsors and collaborators

Lead sponsor

Oregon Health and Science University

Other

Registry information

Official study title

Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Rare Retinal and Choroidal Diseases

Important dates

Study start
2014
Primary completion
2025
Study completion
2026
First posted
May 19, 2014
Registry last updated
Feb 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.